Home

USP2 (human)

Overview USP2 Hydrolase that deubiquitinates polyubiquitinated target proteins such as MDM2, MDM4 and CCND1. Isoform 1 and isoform 4 possess both ubiquitin-specific peptidase and isopeptidase activities. Deubiquitinates MDM2 without reversing MDM2-mediated p53/TP53 ubiquitination and thus indirectly promotes p53/TP53 degradation and limits p53 activity. Has no deubiquitinase activity against p53/TP53. Prevents MDM2-mediated degradation of MDM4. Plays a role in the G1/S cell-cycle progression in normal and cancer cells. Plays a role in the regulation of myogenic differentiation of embryonic muscle cells. Homooligomer. Found in trimeric complex with MDM2 and MDM4 and UPB2. Interacts with CCND1; the interaction is direct and promotes its stabilization by antagonizing ubiquitin-dependent degradation. Interacts (via N-terminus and C- terminus) with MDM2. Interacts with MDM4. Down-regulated by cisplatin. Expressed in mesangial cells of the kidney and in different types of glomerulonephritides. Cleavage is inhibited by ubiquitin in a dosage- dependent manner. Cleavage is blocked by ubiquitin aldehyde. Belongs to the peptidase C19 family. USP2 subfamily. 4 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB. Protein type: EC 3.1.2.15; Ubiquitin-specific protease; EC 3.4.19.12; Protease Cellular Component: centrosome; perinuclear region of cytoplasm; cell cortex; nucleus Molecular Function: ubiquitin thiolesterase activity; identical protein binding; cyclin binding; protein binding; metal ion binding; ubiquitin protein ligase binding; cysteine-type endopeptidase activity Biological Process: ubiquitin-dependent protein catabolic process; negative regulation of skeletal muscle development; muscle development; protein deubiquitination; protein stabilization; positive regulation of skeletal muscle development; negative regulation of transcription from RNA polymerase II promoter; positive regulation of mitotic cell cycle; cell cycle Reference #:  O75604 (UniProtKB) Alt. Names/Synonyms: 41 kDa ubiquitin-specific protease; Deubiquitinating enzyme 2; Ubiquitin carboxyl-terminal hydrolase 2; ubiquitin specific peptidase 2; ubiquitin specific protease 12; ubiquitin specific protease 2; ubiquitin specific protease 9; Ubiquitin thioesterase 2; Ubiquitin-specific-processing protease 2; UBP2; UBP41; USP2; USP9 Gene Symbols: USP2 Molecular weight: 68,072 Da Basal Isoelectric point: 9.15  Predict pI for various phosphorylation states Protein-Specific Antibodies or siRNAs from Cell Signaling Technology®

Select Structure to View Below USP2 2HD5 - A=258-605 (human) 2IBI - B=1-75 (human) 3NHE - A=258-605 (human) 3V6C - A=258-605 (human) 3V6E - A=258-605 (human)

STRING  |  Scansite  |  Phospho.ELM  |  NetworKIN  |  Pfam  |  RCSB PDB 2HD5 2IBI 3NHE 3V6C 3V6E  |  ENZYME  |  Phospho3D  |  DISEASE  |  UniProtKB  |  Entrez-Gene  |  Ensembl Gene

	Modification Sites and Domains	Show Modification Legend
Click here to view phosphorylation modifications only

	Modification Sites in Parent Protein, Orthologs, and Isoforms	Show Modification Legend

SS  SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.	MS  MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.			human ► Hide Isoforms
0	1		-	gap
0	4		-	gap
0	4		-	gap
0	1		-	gap
0	1		R160	LRTSDSYRIDPRNLG
0	1		S490	KRCIKKFSIQRFPKI
0	1		K514	ESRIRTSKLTTFVNF

	USP2 iso4
S34-p	PRSPLSPsLLLstFV
S38-p	LSPsLLLstFVGLLL
T39-p	SPsLLLstFVGLLLN
-	gap
-	gap
S281	KRCIKKFSIQRFPKI
K305	ESRIRTSKLTTFVNF

	mouse
-	gap
-	gap
-	gap
R161-m1	LRTSDGYrTSEGFrI
R167-m1	YrTSEGFrIDPGNLG
S498-p	KRCIKKFsVQRFPKI
K522-u	ESRIRTSkLTTFVNF

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E Produced by 3rd Millennium  |  Design by Digizyme ©2003-2013 Cell Signaling Technology, Inc.